Arcutis anticipates net product revenue of between $455 million and $470 million for the full year 2026.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ARQT:
- Is ARQT a Buy, Before Earnings?
- Arcutis Biotherapeutics presents quality of life, long-term data on ZORYVE
- Arcutis Biotherapeutics: Buy Rating Affirmed Amid FDA Approval and Strategic Growth Initiatives
- Arcutis Biotherapeutics announces FDA approval of ZORYVE cream sNDA
- Arcutis Biotherapeutics announces new Zoryve data at EADV congress